<DOC>
	<DOCNO>NCT02910518</DOCNO>
	<brief_summary>Primary Objective : To demonstrate bioequivalence insulin glulisine give 300 Units/mL test formulation insulin glulisine 100 Units/mL reference formulation single subcutaneous ( SC ) dose . Secondary Objectives : - To assess pharmacodynamic ( PD ) profile pharmacokinetic ( PK ) characteristic insulin glulisine U300 comparison insulin glulisine U100 single SC dose . - To assess safety tolerability test reference formulation insulin glulisine .</brief_summary>
	<brief_title>A Study Demonstrate Bioequivalence Between Insulin Glulisine U300 Insulin Glulisine U100 After Single Subcutaneous Dose Using Euglycemic Clamp Technique , Patients With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>The study duration per patient 18 62 day consist 4 28 day screen period , treatment period 2 day , washout dose occasion 5-18 day , follow visit 7-14 day last dosing .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Inclusion criterion : Male female subject type 1 diabetes mellitus ( T1DM ) 1 year . Total insulin dose &lt; 1.2 U/kg/day . Fasting negative serum Cpeptide ( &lt; 0.30 nmol/L ) . Glycohemoglobin screening ( HbA1c ) ≤9 % . Subjects antiinsulin antibody titer screen ≤30.0 kU/L . Stable insulin regimen least 2 month prior study . Normal find medical history physical examination ( cardiovascular system , chest lung , thyroid , abdomen , nervous system , skin mucosa , musculoskeletal system ) , vital sign , electrocardiogram ( ECG ) , safety laboratory . Exclusion criterion : Any history presence clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic ( apart T1DM ) , hematological , neurological , psychiatric , systemic ( affect body whole ) , ocular , gynecologic ( female ) , infectious disease ; acute infectious disease sign acute illness history presence heparin induce thrombocytopenia Type II ( HITtype II ) . Severe hypoglycemia result coma/seizures require assistance another person , and/or hospitalization diabetic ketoacidosis last 6 month screen visit . Frequent severe headache and/or migraine , recurrent nausea and/or vomit ( twice month ) . Symptomatic hypotension ( whatever decrease blood pressure ) , asymptomatic postural hypotension define decrease systolic blood pressure equal great 20 mmHg within three minute change supine stand position . Presence history drug hypersensitivity , allergic disease diagnose treated physician . Likelihood require treatment study period drug permit clinical study protocol . Any medication ( include medicine contain St John 's Wort ) within 14 day inclusion ( systemic glucocorticoid within 3 month ) within 5 time elimination halflife PD halflife medication , exception insulin , stable treatment ( least 2 month ) thyroid hormone , lipidlowering antihypertensive drug female exception hormonal contraception menopausal hormone replacement therapy . Positive reaction follow test : hepatitis B surface ( HBs Ag ) antigen , anti hepatitis C virus ( antiHCV ) antibody , antihuman immunodeficiency virus 1 2 antibody ( antiHIV1 anti HIV2 Ab ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>